Status:
COMPLETED
The Effect of Black Mulberry (Morus Nigra) Consumption on Cognitive Functions
Lead Sponsor:
Hacettepe University
Collaborating Sponsors:
Yuksek Ihtisas University
Gulhane Training and Research Hospital
Conditions:
Alzheimer Disease, Early Onset
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
The study was conducted with 44 patients who were diagnosed with mild-to-moderate Alzheimer's Disease. Participants were divided into 2 groups intervention group and the control group. The interventio...
Detailed Description
The purpose of this study is to investigate the effects of black mulberry on cognitive functions and biochemical parameters in patients with Alzheimer's disease. The study was conducted in a tertiary ...
Eligibility Criteria
Inclusion
- To be diagnosed with dementia in the first stage
- To be using the same medication for dementia throughout the study
- To have been taking the same dementia medication for the last 6 months and no dose changes for at least 3 months
- Not to have used anthocyanin supplement regularly in the last four months before participating in the study
- Confirmation of medication use by caregivers
- To have a caregiver to follow the patient's daily intake of black mulberry concentrate
Exclusion
- Those under 65 years of age
- Those who have taken new dementia medication in the last 3 months
- Those staying in nursing homes
- Those with mild cognitive impairment who have not yet been diagnosed with dementia
- Those who have cancer
- Those with inflammatory diseases (viral or bacterial)
- History of head trauma that may lead to unconsciousness or other neurological diseases other than dementia
- Those with a defined autoimmune disease
- Alcohol and drug addiction
- Those with major depression
- Those with uncontrollable hypertension
- Those with uncontrolled diabetes
- Those with dysphagia
- Tube fed
- Those who are bedridden
- Delirium
- Those who use drugs that may affect outcome measures, such as benzodiazepines
- Due to the risk that black mulberry may cause possible food-drug interaction via p-glycoprotein / CYP3A in the literature, patients using the drugs named below will not be included in the study.
- Antineoplastic drugs (docetaxel, etoposide, vincristine),
- Calcium channel blockers (eg amlodipine)
- Calcineurin inhibitors (tacrolimus and cyclosporine)
- Digoxin
- Macrolide antibiotics (Clarithromycin)
- Protease inhibitors
Key Trial Info
Start Date :
January 8 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 28 2021
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT05406648
Start Date
January 8 2019
End Date
January 28 2021
Last Update
June 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hacettepe University
Ankara, Turkey (Türkiye), 06100